SMARCD1 and triple-A syndrome: In two mouse models (Angiotensin II-induced model and elastase-induced model), the specific knockout of BAF60a in VSMCs significantly reduced the incidence of AAA, while also reducing vascular inflammation, monocyte infiltration, elastin degradation, and extracellular matrix (ECM) degradation.